The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Free Printed Resources


NAABT opioid addiction treatment resource materials are now available.

*Resources are mailed in a plain white envelope, with "PO Box 333, Farmington, CT 06034" as the return address, no company name on the envelope.

You can order your free resource materials by providing your mailing information below. Also you can sign up to receive our buprenorphine treatment newsletter.

Please check here if you would like to be kept informed about buprenorphine through our e-newsletter by adding your email address to our mailing list.

E-mail Address 

If at any time you wish to unsubscribe, please send an email to unsubscribe@naabt.org

The information you provide below will only be used to fill this order, and not for any other purpose. You are invited to review our Terms and Privacy Policy online at http://www.naabt.org/global_privacy.cfm

To order free printed resources on opioid addiction and buprenorphine treatment, please fill out the information below.

Buprenorphine resources picture*Items with an asterisk are required.

Buprenorphine Brochure Emergency Wallet Card Addiction Survivors Peer Support Brochure
First Name*
Last Name*
Address*
Address 2
City*
State*
Zip Code*

Where did you hear about this resource?


    

This page was last modified on : 04/13/2016

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine Rejected by FDA 4/30/2013 - may resubmit in late 2015 - Probuphine denied by FDA